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in each group was calculated. Tumor multiplicity was defined as
the average number of tumors per mice, obtained by dividing
the total number of tumors by the total number of mice per group,
including non-tumor bearing animals.
Bronchoalveolar lavage (BAL) of lungs was performed on 6
mice (animals were anesthetized by an ip injection of sodium
thiopental) from each study group at the 1, 7, 15 and 30 days after
irradiation and SO2 inhalation. Total cells of BAL were counted
using hemocytometer chamber and an optical microscope with
a 400 zoom. BAL differential cell (macrophages, lymphocytes,
eosinophiles and neutrophils) counts were performed on slides
(Romanowsky stain). Phagocytic activity of AM was counted on
slides. AM morphometric study was done by measuring the area
of each cell (square of cell) and the area of nuclear of each cell
(square of nuclear) with use of the original image analyzer com-
puter system.
Results: Results of the combined effects of radiation and
inhalation of sulfur dioxide showed the growth of tumor quantity
in the lung: the frequency of adenomas/mouse was more than
42% higher than that of control group. Synergism coefficient
was 1.1 in this case.
Irradiation at a dose of 1.0 Gymodifies the reaction of free cells
of lung on the action of sulfur dioxide, which is manifested in the
change of the number of cells in the BAL fluid, the phagocytic
activity of the AM, as well as of the changes the morphometric
parameters of their cells.
Conclusion: Thus, if the amount of radiation exposure of BAL
cells was significantly reduced by the 1st and 7th days, and after
inhalation of sulfur dioxide – tended to increase, then the com-
bined action on the 7th day it was almost half the theoretical
(hypothetical) the sum of the separate effects of the studied fac-
tors. Exposure to sulfur dioxide significantly slowed the activation
of cell count. It was found, that after combined action of the
investigated factors the morphological characteristics of macro-
phages (reducing the square of cells and their nuclei) have
changed (7th and 15th day). The absorption activity of phagocytes
was significantly reduced (7 day).
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Background: Despite the abundance of theoretical evidences
displaying the considerable role of the ‘‘soil” in metastasis
progression, the majority of cancer research and cancer therapy
pathogenetic methods focused mainly on the tumor cells. There
is still no clear clinical data showing the role of ‘‘soil” in the
metastasis. Identification of factors and mechanisms driving
the conditions promoting tumor dissemination may lead to
therapeutic strategy to detect and prevent metastases at the
earliest step. It has been established that bone marrow-derived
hematopoietic progenitor cells home to pre-metastatic sites
before tumor cells infiltrate in these sites. These hematopoietic
progenitor cells form regulatory cell cluster of stromal microenvi-
ronment (premetastatic niche) to promote secondary tumor
growth. In this context, the aim of our study was to evaluate
the level of different pools of circulating tumor cells and bone
marrow progenitor cells in the blood of patients with breast
cancer in the dynamics of neoadjuvant chemotherapy.
Materials and methods: Patients (prospective study) with
newly diagnosed invasive breast cancer in the age range 18–50
years and tumor volume of 2.0(> or =) cm, referred at the Tomsk
Cancer Research Institute for treatment were included into the
study. Eligibility criteria were as follows: the patient’s informed
consent to participate in research; morphologically verified diag-
nosis of invasive carcinoma of non-specific type; luminal B-1, -2,
triple negative (basal-like subtype included), HER2 positive breast
cancer; T2-4N0-3M0; preserved menstrual function; satisfactory
performance status (on a scale (< or =) ECOG 2). Exclusion Criteria
were: other than luminal histological type of breast cancer,
multiple primary cancer; chronic inflammatory diseases in the
acute stage. Samples of venous blood taken from breast cancer
patients before biopsy, after biopsy and after each subsequent
course of neoadjuvant chemotherapy (NACHT) were served as a
study material. The various pools of circulating tumor cells and
bone-marrow derived progenitor cells were determined using
monoclonal antibodies to EpCam, CD44, CD45, CD24,
N-cadherin, CD34, CD133, CD202, VEGFR1 and CD90, labeled with
different fluorochromes on flow cytometry BD FACSCanto TM II.
Results: The study showed that each succeeding course of
NACHT increased blood levels of circulating tumor cells, and bone
marrow progenitor cells with a phenotype characteristic of EPC
(endothelial progenitor cells) (CD34 + CD45–VEGFR + CD133
+ CD202 +) and MSC (mesenchymal progenitor stem cells
fibroblasts) (CD34–CD90 + VEGFR1–CD45–CD202–). Influence of
the NACHT on hematopoietic stem cells HSC (VEGFR1 + CD34 +
CD45lowSD202–) and progenitor cells HPC – CD34 + CD45 +
CD90–VEGFR1 + CD133 – was ambiguous.
Conclusion: Neoadjuvant chemotherapy increases blood levels
of circulating tumor cells, endothelial progenitor cells and mes-
enchymal stem cells progenitor fibroblasts, thus promoting the
formation of premetastatic niche.
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